PT - JOURNAL ARTICLE AU - Ibrahim, Danyal AU - Dulipsingh, Latha AU - Zapatka, Lisa AU - Eadie, Reginald AU - Crowell, Rebecca AU - Williams, Kendra AU - Wakefield, Dorothy B. AU - Cook, Lisa AU - Puff, Jennifer AU - Hussain, Syed A. TI - Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial AID - 10.1101/2020.08.27.20183293 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.27.20183293 4099 - http://medrxiv.org/content/early/2020/09/01/2020.08.27.20183293.short 4100 - http://medrxiv.org/content/early/2020/09/01/2020.08.27.20183293.full AB - We conducted a prospective single-arm open-label phase II clinical trial assessing the safety and efficacy of convalescent plasma in hospitalized COVID-19 patients. Convalescent plasma with sufficient IgG titer (1:320) obtained from recovered donors was administered to adult patients with either severe or critical COVID-19 illness. Primary outcomes were adverse events in association with plasma administration, and hospital mortality. Secondary outcomes included disease progression, recovery, length of stay, and hospital discharge. Of the 38 patients included in the analysis, 24 (63%) recovered and were discharged, and 14 (37%) died. Patients who received convalescent plasma early in the disease course (severe illness group) as compared to the patients that received convalescent plasma later in disease progression (critical illness group) had significantly lower hospital mortality 13% vs 55% (p<0.02) and shorter mean hospital length of stay 15.4 vs 33 days (p<0.01). One patient experienced a transient transfusion reaction. No other adverse effects of convalescent plasma infusion were observed. Our results suggest that convalescent plasma is safe and has the potential for positive impact on clinical outcomes including recovery and survival if given to patients early in the course of COVID-19 disease.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04343261 IND #19805Funding StatementThis study was supported by funds from Trinity Health Of New England, a not-for-profit healthcare organizationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the Trinity Health Of New England Institutional Review Board (#SFH-20-23)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData details is summarized and included in this submission. Patient level data without PHI is available upon request.